Steve MacMillan'un ücretlendirmesi Hologic'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 28 2024	n/a	n/a	US$790m
Jun 29 2024	n/a	n/a	US$702m
Mar 30 2024	n/a	n/a	US$467m
Dec 30 2023	n/a	n/a	US$515m
Sep 30 2023	US$16m	US$1m	US$456m
Jul 01 2023	n/a	n/a	US$484m
Apr 01 2023	n/a	n/a	US$753m
Dec 31 2022	n/a	n/a	US$990m
Sep 24 2022	US$14m	US$1m	US$1b
Jun 25 2022	n/a	n/a	US$2b
Mar 26 2022	n/a	n/a	US$2b
Dec 25 2021	n/a	n/a	US$2b
Sep 25 2021	US$15m	US$1m	US$2b
Jun 26 2021	n/a	n/a	US$2b
Mar 27 2021	n/a	n/a	US$2b
Dec 26 2020	n/a	n/a	US$1b
Sep 26 2020	US$14m	US$1m	US$1b
Jun 27 2020	n/a	n/a	US$497m
Mar 28 2020	n/a	n/a	US$453m
Dec 28 2019	n/a	n/a	US$84m
Sep 28 2019	US$12m	US$1m	-US$204m
Jun 29 2019	n/a	n/a	-US$30m
Mar 30 2019	n/a	n/a	-US$11m
Dec 29 2018	n/a	n/a	-US$419m
Sep 29 2018	US$42m	US$1m	-US$111m

Tazminat ve Piyasa: Steve 'ın toplam tazminatı ($USD 15.56M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 12.85M ).

Tazminat ve Kazançlar: Steve 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Steve MacMillan (60 yo)

11yrs

Görev süresi

US$15,555,032

Tazminat

Mr. Stephen P. MacMillan, also known as Steve, serves as an Independent Chairman of the Board at Illumina, Inc. from June 02, 2023. He has been the Chairman of the Board at Hologic Inc. since June 17, 2015...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Stephen MacMillan	Chairman	11yrs	US$15.56m	1.05% $ 170.6m
Karleen Oberton	Chief Financial Officer	6.3yrs	US$3.93m	0.045% $ 7.3m
Essex Mitchell	Chief Operating Officer	less than a year	US$2.17m	0.012% $ 2.0m
John Griffin	General Counsel	9.8yrs	US$3.34m	0.080% $ 13.1m
Jan Verstreken	Group President of International	no data	US$3.52m	0.046% $ 7.4m
Paul Malenchini	Chief Information Officer	3.4yrs	Veri yok	Veri yok
Ryan Simon	Vice President of Investor Relations	no data	Veri yok	Veri yok
Diana De Walt	Senior Vice President of Global Human Resources	less than a year	Veri yok	Veri yok
Monica Berthelot	VP & Chief of Staff	10.9yrs	Veri yok	Veri yok
Erik Anderson	Division President of Breast & Skeletal Health Solutions	4.3yrs	Veri yok	0.010% $ 1.7m
Jennifer Schneiders	President of Diagnostics Solutions	1.7yrs	Veri yok	0.0053% $ 866.7k
Scott Christensen	Senior Vice President of Global Supply Chain	1.2yrs	Veri yok	Veri yok

3.9yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: HOLX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.9 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Stephen MacMillan	Chairman	11yrs	US$15.56m	1.05% $ 170.6m
Scott Garrett	Independent Director	11.6yrs	US$339.96k	0.019% $ 3.0m
Sally Crawford	Independent Director	17.2yrs	US$374.96k	0.058% $ 9.4m
Martin Madaus	Director	no data	Veri yok	Veri yok
Stacey Stewart	Independent Director	1.9yrs	US$338.44k	0.000070% $ 11.4k
Ludwig Hantson	Independent Director	6.1yrs	US$319.96k	0.0026% $ 417.9k
Charles Dockendorff	Independent Director	7.6yrs	US$344.96k	0.0068% $ 1.1m
Christiana Stamoulis	Independent Director	13.1yrs	US$319.96k	0.019% $ 3.1m
Amy Wendell	Lead Independent Director	8yrs	US$319.96k	0.0078% $ 1.3m
Nanaz Mohtashami	Independent Director	1.3yrs	US$128.96k	0.00033% $ 53.7k

7.8yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: HOLX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.8 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/22 21:40
Gün Sonu Hisse Fiyatı	2024/12/20 00:00
Kazançlar	2024/09/28
Yıllık Kazançlar	2024/09/28

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Hologic, Inc. 51 Bu analistlerden 20, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
David Toung	Argus Research Company
Ishan Majumdar	Baptista Research
Charles Butler	Barclays

Hologic Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Chief Operating Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Chairman notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Hologic, Inc., Annual General Meeting, Mar 07, 2024

Namal Nawana Announces Not to Stand for Re-Election to the Board of Hologic, Inc

Recent updates

Earnings Not Telling The Story For Hologic, Inc. (NASDAQ:HOLX)

Hologic, Inc. Announces New Data to Be Presented At SABCS 2024 Investigates the Potential Role of the Breast Cancer Index Test in Identifying Patients with Minimal Risk of Distant Recurrence

Chief Operating Officer notifies of intention to sell stock

Hologic, Inc.'s (NASDAQ:HOLX) Intrinsic Value Is Potentially 60% Above Its Share Price

Hologic, Inc. to Showcase AI-Powered Breast Imaging Advancements Designed to Assess Breast Density, Enhance Workflows and Improve Cancer Detection

Hologic, Inc. Provides Earnings Guidance for the First Quarter and Fiscal Year of 2025

When Should You Buy Hologic, Inc. (NASDAQ:HOLX)?

Hologic: Continued Room Amidst Bolt-On M&A Efforts

Hologic (NASDAQ:HOLX) Seems To Use Debt Rather Sparingly

Hologic, Inc. (NasdaqGS:HOLX) agreed to acquire Gynesonics, Inc. for $350 million.

Hologic, Inc. to Report Q4, 2024 Results on Nov 04, 2024

Hologic (NASDAQ:HOLX) Has More To Do To Multiply In Value Going Forward

Hologic, Inc. (NasdaqGS:HOLX) announces an Equity Buyback for $1,500 million worth of its shares.

Hologic, Inc. (NASDAQ:HOLX) Not Flying Under The Radar

Chief Financial Officer notifies of intention to sell stock

Hologic Has A Lot Of Fine Qualities, But A Discount Valuation Isn't Among Them

Chairman notifies of intention to sell stock

Hologic, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Hologic, Inc. (NasdaqGS:HOLX) completed the acquisition of Endomagnetics Ltd. for approximately $310 million.

Is There Now An Opportunity In Hologic, Inc. (NASDAQ:HOLX)?

Hologic, Inc. to Report Q3, 2024 Results on Jul 29, 2024

Now 19% undervalued after recent price drop

Now 20% undervalued after recent price drop

These 4 Measures Indicate That Hologic (NASDAQ:HOLX) Is Using Debt Reasonably Well

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Returns At Hologic (NASDAQ:HOLX) Appear To Be Weighed Down

Hologic: Women's Health Play Looks Healthier Itself

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Hologic, Inc. Reports Impairment of Intangible Assets for the Second Quarter Ended March 30, 2024

Hologic, Inc. (NasdaqGS:HOLX) signed a definitive agreement to acquire Endomagnetics Ltd. for approximately $310 million.

Getting In Cheap On Hologic, Inc. (NASDAQ:HOLX) Might Be Difficult

Now 20% undervalued

Calculating The Intrinsic Value Of Hologic, Inc. (NASDAQ:HOLX)

Hologic, Inc. to Report Q2, 2024 Results on May 02, 2024

Hologic (NASDAQ:HOLX) Has A Pretty Healthy Balance Sheet

Independent Director notifies of intention to sell stock

Now 20% undervalued

Hologic, Inc. and Biotheranostics, Inc. Announces Newly Published Study Results Reveal That Use of the Breast Cancer Index®? Test

Now 20% undervalued

Why Hologic, Inc. (NASDAQ:HOLX) Could Be Worth Watching

Hologic: Prospects For Growth As Headwinds Disappear

We Think You Can Look Beyond Hologic's (NASDAQ:HOLX) Lackluster Earnings

Hologic, Inc. Just Beat EPS By 32%: Here's What Analysts Think Will Happen Next

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2024

We Like These Underlying Return On Capital Trends At Hologic (NASDAQ:HOLX)

Now 21% undervalued

Hologic, Inc., Annual General Meeting, Mar 07, 2024

Namal Nawana Announces Not to Stand for Re-Election to the Board of Hologic, Inc

Now 21% undervalued

Hologic, Inc. Provides Revenue Guidance for the First Quarter of 2024

Hologic, Inc. to Report Q1, 2024 Results on Feb 01, 2024

Independent Director notifies of intention to sell stock

The Price Is Right For Hologic, Inc. (NASDAQ:HOLX)

Hologic, Inc. Promotes Essex D. Mitchell to Chief Operating Officer

Chairman exercised options and sold US$2.1m worth of stock

Hologic, Inc. Provides Earnings Guidance for the First Quarter and Full-Year Fiscal 2024

Full year 2023 earnings: EPS misses analyst expectations

Hologic, Inc. (NasdaqGS:HOLX) announces an Equity Buyback for $500 million worth of its shares.

Hologic, Inc. to Report Q4, 2023 Results on Nov 09, 2023

Nanaz Mohtashami Elected to Hologic, Inc.'S Board of Directors

Consensus EPS estimates fall by 22%

Hologic, Inc. Reports Impairment Charges for the Third Quarter Ended July 1, 2023

New minor risk - Earnings quality

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2023

Hologic, Inc. to Report Q3, 2023 Results on Jul 31, 2023